An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer

Trial Profile

An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Athenex
  • Most Recent Events

    • 17 Nov 2016 Last Checked against ClinicalTrials.gov record.
    • 04 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top